nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—ABCB1—Mitomycin—urinary bladder cancer	0.152	0.207	CbGbCtD
Mirabegron—BCHE—Cisplatin—urinary bladder cancer	0.125	0.171	CbGbCtD
Mirabegron—SLCO1A2—Methotrexate—urinary bladder cancer	0.0764	0.104	CbGbCtD
Mirabegron—ALB—Fluorouracil—urinary bladder cancer	0.0715	0.0975	CbGbCtD
Mirabegron—CYP3A4—Thiotepa—urinary bladder cancer	0.069	0.094	CbGbCtD
Mirabegron—ABCB1—Gemcitabine—urinary bladder cancer	0.0438	0.0596	CbGbCtD
Mirabegron—ALB—Methotrexate—urinary bladder cancer	0.0395	0.0538	CbGbCtD
Mirabegron—ABCB1—Cisplatin—urinary bladder cancer	0.0318	0.0433	CbGbCtD
Mirabegron—ABCB1—Etoposide—urinary bladder cancer	0.0312	0.0426	CbGbCtD
Mirabegron—ABCB1—Doxorubicin—urinary bladder cancer	0.0213	0.029	CbGbCtD
Mirabegron—ABCB1—Methotrexate—urinary bladder cancer	0.0206	0.0281	CbGbCtD
Mirabegron—CYP2D6—Doxorubicin—urinary bladder cancer	0.0201	0.0274	CbGbCtD
Mirabegron—CYP3A4—Etoposide—urinary bladder cancer	0.0187	0.0255	CbGbCtD
Mirabegron—CYP3A4—Doxorubicin—urinary bladder cancer	0.0128	0.0174	CbGbCtD
Mirabegron—ADRB3—prostate gland—urinary bladder cancer	0.00566	0.161	CbGeAlD
Mirabegron—ADRB3—female reproductive system—urinary bladder cancer	0.00309	0.0879	CbGeAlD
Mirabegron—CYP3A4—urine—urinary bladder cancer	0.00305	0.0868	CbGeAlD
Mirabegron—CYP2D6—urine—urinary bladder cancer	0.003	0.0854	CbGeAlD
Mirabegron—ORM1—prostate gland—urinary bladder cancer	0.00262	0.0747	CbGeAlD
Mirabegron—BCHE—prostate gland—urinary bladder cancer	0.00163	0.0463	CbGeAlD
Mirabegron—SLCO1A2—renal system—urinary bladder cancer	0.00158	0.0449	CbGeAlD
Mirabegron—ORM1—female reproductive system—urinary bladder cancer	0.00143	0.0408	CbGeAlD
Mirabegron—BCHE—seminal vesicle—urinary bladder cancer	0.00138	0.0392	CbGeAlD
Mirabegron—BCHE—smooth muscle tissue—urinary bladder cancer	0.00115	0.0328	CbGeAlD
Mirabegron—BCHE—female reproductive system—urinary bladder cancer	0.000888	0.0253	CbGeAlD
Mirabegron—ORM1—lymph node—urinary bladder cancer	0.000838	0.0238	CbGeAlD
Mirabegron—BCHE—vagina—urinary bladder cancer	0.000803	0.0229	CbGeAlD
Mirabegron—ABCB1—prostate gland—urinary bladder cancer	0.000775	0.0221	CbGeAlD
Mirabegron—Urethral disorder—Gemcitabine—urinary bladder cancer	0.000767	0.00368	CcSEcCtD
Mirabegron—Vision blurred—Thiotepa—urinary bladder cancer	0.000764	0.00366	CcSEcCtD
Mirabegron—Vaginal infection—Methotrexate—urinary bladder cancer	0.000753	0.00361	CcSEcCtD
Mirabegron—CYP3A4—renal system—urinary bladder cancer	0.000746	0.0212	CbGeAlD
Mirabegron—Infestation—Etoposide—urinary bladder cancer	0.000745	0.00357	CcSEcCtD
Mirabegron—Infestation NOS—Etoposide—urinary bladder cancer	0.000745	0.00357	CcSEcCtD
Mirabegron—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.00074	0.00355	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Etoposide—urinary bladder cancer	0.000738	0.00354	CcSEcCtD
Mirabegron—ALB—lymph node—urinary bladder cancer	0.000735	0.0209	CbGeAlD
Mirabegron—CYP2D6—renal system—urinary bladder cancer	0.000735	0.0209	CbGeAlD
Mirabegron—Cystitis noninfective—Epirubicin—urinary bladder cancer	0.000729	0.00349	CcSEcCtD
Mirabegron—Cardiac disorder—Gemcitabine—urinary bladder cancer	0.000727	0.00348	CcSEcCtD
Mirabegron—Neoplasm—Methotrexate—urinary bladder cancer	0.000721	0.00345	CcSEcCtD
Mirabegron—Bladder pain—Methotrexate—urinary bladder cancer	0.000721	0.00345	CcSEcCtD
Mirabegron—Urinary tract disorder—Cisplatin—urinary bladder cancer	0.000721	0.00345	CcSEcCtD
Mirabegron—Cystitis—Epirubicin—urinary bladder cancer	0.000721	0.00345	CcSEcCtD
Mirabegron—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000717	0.00344	CcSEcCtD
Mirabegron—Urethral disorder—Cisplatin—urinary bladder cancer	0.000715	0.00343	CcSEcCtD
Mirabegron—Vaginal infection—Epirubicin—urinary bladder cancer	0.000704	0.00338	CcSEcCtD
Mirabegron—Hypertension—Thiotepa—urinary bladder cancer	0.000699	0.00335	CcSEcCtD
Mirabegron—Arthralgia—Thiotepa—urinary bladder cancer	0.00069	0.0033	CcSEcCtD
Mirabegron—Dry eye—Epirubicin—urinary bladder cancer	0.000689	0.0033	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000685	0.00328	CcSEcCtD
Mirabegron—Eye disorder—Cisplatin—urinary bladder cancer	0.000682	0.00327	CcSEcCtD
Mirabegron—Cardiac disorder—Cisplatin—urinary bladder cancer	0.000677	0.00324	CcSEcCtD
Mirabegron—Bladder pain—Epirubicin—urinary bladder cancer	0.000675	0.00323	CcSEcCtD
Mirabegron—Neoplasm—Epirubicin—urinary bladder cancer	0.000675	0.00323	CcSEcCtD
Mirabegron—Cystitis noninfective—Doxorubicin—urinary bladder cancer	0.000674	0.00323	CcSEcCtD
Mirabegron—Cystitis—Doxorubicin—urinary bladder cancer	0.000667	0.00319	CcSEcCtD
Mirabegron—Urinary tract disorder—Etoposide—urinary bladder cancer	0.00066	0.00316	CcSEcCtD
Mirabegron—Back pain—Gemcitabine—urinary bladder cancer	0.000659	0.00316	CcSEcCtD
Mirabegron—Infection—Thiotepa—urinary bladder cancer	0.000657	0.00315	CcSEcCtD
Mirabegron—ABCB1—seminal vesicle—urinary bladder cancer	0.000656	0.0187	CbGeAlD
Mirabegron—Urethral disorder—Etoposide—urinary bladder cancer	0.000655	0.00314	CcSEcCtD
Mirabegron—Vaginal infection—Doxorubicin—urinary bladder cancer	0.000652	0.00312	CcSEcCtD
Mirabegron—Tachycardia—Thiotepa—urinary bladder cancer	0.000645	0.00309	CcSEcCtD
Mirabegron—Skin disorder—Thiotepa—urinary bladder cancer	0.000642	0.00308	CcSEcCtD
Mirabegron—Dry eye—Doxorubicin—urinary bladder cancer	0.000638	0.00306	CcSEcCtD
Mirabegron—Erythema multiforme—Etoposide—urinary bladder cancer	0.000632	0.00303	CcSEcCtD
Mirabegron—Vision blurred—Fluorouracil—urinary bladder cancer	0.000631	0.00303	CcSEcCtD
Mirabegron—Eye disorder—Etoposide—urinary bladder cancer	0.000625	0.00299	CcSEcCtD
Mirabegron—Neoplasm—Doxorubicin—urinary bladder cancer	0.000624	0.00299	CcSEcCtD
Mirabegron—Bladder pain—Doxorubicin—urinary bladder cancer	0.000624	0.00299	CcSEcCtD
Mirabegron—Cardiac disorder—Etoposide—urinary bladder cancer	0.00062	0.00297	CcSEcCtD
Mirabegron—Vascular purpura—Epirubicin—urinary bladder cancer	0.000606	0.0029	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000602	0.00289	CcSEcCtD
Mirabegron—Vision blurred—Cisplatin—urinary bladder cancer	0.000599	0.00287	CcSEcCtD
Mirabegron—CYP3A4—female reproductive system—urinary bladder cancer	0.000598	0.017	CbGeAlD
Mirabegron—Cerebrovascular accident—Methotrexate—urinary bladder cancer	0.000591	0.00283	CcSEcCtD
Mirabegron—Hypertension—Gemcitabine—urinary bladder cancer	0.000588	0.00282	CcSEcCtD
Mirabegron—CYP2D6—female reproductive system—urinary bladder cancer	0.000588	0.0167	CbGeAlD
Mirabegron—Dyspepsia—Thiotepa—urinary bladder cancer	0.000582	0.00279	CcSEcCtD
Mirabegron—Arthralgia—Gemcitabine—urinary bladder cancer	0.00058	0.00278	CcSEcCtD
Mirabegron—Osteoarthritis—Methotrexate—urinary bladder cancer	0.000579	0.00277	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000576	0.00276	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000571	0.00273	CcSEcCtD
Mirabegron—Fatigue—Thiotepa—urinary bladder cancer	0.00057	0.00273	CcSEcCtD
Mirabegron—ABCB1—epithelium—urinary bladder cancer	0.00057	0.0162	CbGeAlD
Mirabegron—Constipation—Thiotepa—urinary bladder cancer	0.000565	0.00271	CcSEcCtD
Mirabegron—Back pain—Etoposide—urinary bladder cancer	0.000563	0.0027	CcSEcCtD
Mirabegron—Purpura—Epirubicin—urinary bladder cancer	0.000562	0.00269	CcSEcCtD
Mirabegron—Vascular purpura—Doxorubicin—urinary bladder cancer	0.00056	0.00268	CcSEcCtD
Mirabegron—Cerebrovascular accident—Epirubicin—urinary bladder cancer	0.000553	0.00265	CcSEcCtD
Mirabegron—Infection—Gemcitabine—urinary bladder cancer	0.000553	0.00265	CcSEcCtD
Mirabegron—Infection—Fluorouracil—urinary bladder cancer	0.000543	0.0026	CcSEcCtD
Mirabegron—Osteoarthritis—Epirubicin—urinary bladder cancer	0.000542	0.0026	CcSEcCtD
Mirabegron—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000541	0.00259	CcSEcCtD
Mirabegron—Skin disorder—Gemcitabine—urinary bladder cancer	0.00054	0.00259	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000537	0.00257	CcSEcCtD
Mirabegron—Tachycardia—Fluorouracil—urinary bladder cancer	0.000534	0.00256	CcSEcCtD
Mirabegron—ABCB1—renal system—urinary bladder cancer	0.000528	0.015	CbGeAlD
Mirabegron—Urticaria—Thiotepa—urinary bladder cancer	0.000525	0.00252	CcSEcCtD
Mirabegron—Breast disorder—Methotrexate—urinary bladder cancer	0.000523	0.00251	CcSEcCtD
Mirabegron—Abdominal pain—Thiotepa—urinary bladder cancer	0.000523	0.0025	CcSEcCtD
Mirabegron—Purpura—Doxorubicin—urinary bladder cancer	0.00052	0.00249	CcSEcCtD
Mirabegron—BCHE—lymph node—urinary bladder cancer	0.000519	0.0148	CbGeAlD
Mirabegron—ABCB1—urethra—urinary bladder cancer	0.000519	0.0148	CbGeAlD
Mirabegron—Infection—Cisplatin—urinary bladder cancer	0.000515	0.00247	CcSEcCtD
Mirabegron—Cerebrovascular accident—Doxorubicin—urinary bladder cancer	0.000511	0.00245	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000507	0.00243	CcSEcCtD
Mirabegron—Tachycardia—Cisplatin—urinary bladder cancer	0.000506	0.00242	CcSEcCtD
Mirabegron—Skin disorder—Cisplatin—urinary bladder cancer	0.000504	0.00241	CcSEcCtD
Mirabegron—Hypertension—Etoposide—urinary bladder cancer	0.000502	0.00241	CcSEcCtD
Mirabegron—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000501	0.0024	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000498	0.00239	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000492	0.00236	CcSEcCtD
Mirabegron—Breast disorder—Epirubicin—urinary bladder cancer	0.000489	0.00235	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Epirubicin—urinary bladder cancer	0.000488	0.00234	CcSEcCtD
Mirabegron—Nasopharyngitis—Epirubicin—urinary bladder cancer	0.000484	0.00232	CcSEcCtD
Mirabegron—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000481	0.00231	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.00048	0.0023	CcSEcCtD
Mirabegron—Fatigue—Gemcitabine—urinary bladder cancer	0.00048	0.0023	CcSEcCtD
Mirabegron—Gastritis—Epirubicin—urinary bladder cancer	0.000479	0.0023	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Epirubicin—urinary bladder cancer	0.000478	0.00229	CcSEcCtD
Mirabegron—Constipation—Gemcitabine—urinary bladder cancer	0.000476	0.00228	CcSEcCtD
Mirabegron—Asthenia—Thiotepa—urinary bladder cancer	0.000474	0.00227	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000472	0.00226	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000472	0.00226	CcSEcCtD
Mirabegron—Infection—Etoposide—urinary bladder cancer	0.000472	0.00226	CcSEcCtD
Mirabegron—Abdominal distension—Epirubicin—urinary bladder cancer	0.000471	0.00226	CcSEcCtD
Mirabegron—Influenza—Epirubicin—urinary bladder cancer	0.000468	0.00224	CcSEcCtD
Mirabegron—Pruritus—Thiotepa—urinary bladder cancer	0.000468	0.00224	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000465	0.00223	CcSEcCtD
Mirabegron—Tachycardia—Etoposide—urinary bladder cancer	0.000464	0.00222	CcSEcCtD
Mirabegron—Skin disorder—Etoposide—urinary bladder cancer	0.000461	0.00221	CcSEcCtD
Mirabegron—Breast disorder—Doxorubicin—urinary bladder cancer	0.000453	0.00217	CcSEcCtD
Mirabegron—Diarrhoea—Thiotepa—urinary bladder cancer	0.000452	0.00217	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000451	0.00216	CcSEcCtD
Mirabegron—Nasopharyngitis—Doxorubicin—urinary bladder cancer	0.000448	0.00215	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000448	0.00214	CcSEcCtD
Mirabegron—Infestation NOS—Methotrexate—urinary bladder cancer	0.000446	0.00214	CcSEcCtD
Mirabegron—Infestation—Methotrexate—urinary bladder cancer	0.000446	0.00214	CcSEcCtD
Mirabegron—Gastritis—Doxorubicin—urinary bladder cancer	0.000444	0.00212	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000442	0.00212	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000442	0.00212	CcSEcCtD
Mirabegron—Dizziness—Thiotepa—urinary bladder cancer	0.000437	0.00209	CcSEcCtD
Mirabegron—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000436	0.00209	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000435	0.00208	CcSEcCtD
Mirabegron—Urticaria—Fluorouracil—urinary bladder cancer	0.000434	0.00208	CcSEcCtD
Mirabegron—Influenza—Doxorubicin—urinary bladder cancer	0.000433	0.00208	CcSEcCtD
Mirabegron—ABCB1—female reproductive system—urinary bladder cancer	0.000423	0.012	CbGeAlD
Mirabegron—Infestation—Epirubicin—urinary bladder cancer	0.000417	0.002	CcSEcCtD
Mirabegron—Infestation NOS—Epirubicin—urinary bladder cancer	0.000417	0.002	CcSEcCtD
Mirabegron—Rash—Thiotepa—urinary bladder cancer	0.000417	0.002	CcSEcCtD
Mirabegron—Dermatitis—Thiotepa—urinary bladder cancer	0.000417	0.002	CcSEcCtD
Mirabegron—Headache—Thiotepa—urinary bladder cancer	0.000414	0.00198	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000414	0.00198	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.00041	0.00196	CcSEcCtD
Mirabegron—Fatigue—Etoposide—urinary bladder cancer	0.000409	0.00196	CcSEcCtD
Mirabegron—Constipation—Etoposide—urinary bladder cancer	0.000406	0.00195	CcSEcCtD
Mirabegron—Urinary tract infection—Epirubicin—urinary bladder cancer	0.000406	0.00194	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000403	0.00193	CcSEcCtD
Mirabegron—Asthenia—Gemcitabine—urinary bladder cancer	0.000399	0.00191	CcSEcCtD
Mirabegron—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000395	0.00189	CcSEcCtD
Mirabegron—Pruritus—Gemcitabine—urinary bladder cancer	0.000394	0.00189	CcSEcCtD
Mirabegron—Nausea—Thiotepa—urinary bladder cancer	0.000393	0.00188	CcSEcCtD
Mirabegron—Urethral disorder—Methotrexate—urinary bladder cancer	0.000393	0.00188	CcSEcCtD
Mirabegron—Sinusitis—Epirubicin—urinary bladder cancer	0.000392	0.00188	CcSEcCtD
Mirabegron—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000388	0.00186	CcSEcCtD
Mirabegron—Pruritus—Fluorouracil—urinary bladder cancer	0.000387	0.00185	CcSEcCtD
Mirabegron—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000386	0.00185	CcSEcCtD
Mirabegron—Infestation—Doxorubicin—urinary bladder cancer	0.000386	0.00185	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000383	0.00183	CcSEcCtD
Mirabegron—ABCB1—vagina—urinary bladder cancer	0.000383	0.0109	CbGeAlD
Mirabegron—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000381	0.00182	CcSEcCtD
Mirabegron—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000379	0.00181	CcSEcCtD
Mirabegron—Urticaria—Etoposide—urinary bladder cancer	0.000377	0.00181	CcSEcCtD
Mirabegron—Rhinitis—Epirubicin—urinary bladder cancer	0.000376	0.0018	CcSEcCtD
Mirabegron—Abdominal pain—Etoposide—urinary bladder cancer	0.000375	0.0018	CcSEcCtD
Mirabegron—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000375	0.0018	CcSEcCtD
Mirabegron—Eye disorder—Methotrexate—urinary bladder cancer	0.000374	0.00179	CcSEcCtD
Mirabegron—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000374	0.00179	CcSEcCtD
Mirabegron—Asthenia—Cisplatin—urinary bladder cancer	0.000372	0.00178	CcSEcCtD
Mirabegron—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000372	0.00178	CcSEcCtD
Mirabegron—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.00037	0.00177	CcSEcCtD
Mirabegron—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000368	0.00176	CcSEcCtD
Mirabegron—Urethral disorder—Epirubicin—urinary bladder cancer	0.000367	0.00176	CcSEcCtD
Mirabegron—Sinusitis—Doxorubicin—urinary bladder cancer	0.000362	0.00174	CcSEcCtD
Mirabegron—Dizziness—Fluorouracil—urinary bladder cancer	0.000362	0.00173	CcSEcCtD
Mirabegron—Diarrhoea—Cisplatin—urinary bladder cancer	0.000355	0.0017	CcSEcCtD
Mirabegron—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000354	0.0017	CcSEcCtD
Mirabegron—Rash—Gemcitabine—urinary bladder cancer	0.000351	0.00168	CcSEcCtD
Mirabegron—Dermatitis—Gemcitabine—urinary bladder cancer	0.00035	0.00168	CcSEcCtD
Mirabegron—Eye disorder—Epirubicin—urinary bladder cancer	0.00035	0.00168	CcSEcCtD
Mirabegron—Headache—Gemcitabine—urinary bladder cancer	0.000348	0.00167	CcSEcCtD
Mirabegron—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000348	0.00167	CcSEcCtD
Mirabegron—Rhinitis—Doxorubicin—urinary bladder cancer	0.000348	0.00167	CcSEcCtD
Mirabegron—Rash—Fluorouracil—urinary bladder cancer	0.000345	0.00165	CcSEcCtD
Mirabegron—Dermatitis—Fluorouracil—urinary bladder cancer	0.000344	0.00165	CcSEcCtD
Mirabegron—Headache—Fluorouracil—urinary bladder cancer	0.000343	0.00164	CcSEcCtD
Mirabegron—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000342	0.00164	CcSEcCtD
Mirabegron—Asthenia—Etoposide—urinary bladder cancer	0.000341	0.00163	CcSEcCtD
Mirabegron—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000341	0.00163	CcSEcCtD
Mirabegron—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00034	0.00163	CcSEcCtD
Mirabegron—Back pain—Methotrexate—urinary bladder cancer	0.000337	0.00162	CcSEcCtD
Mirabegron—Pruritus—Etoposide—urinary bladder cancer	0.000336	0.00161	CcSEcCtD
Mirabegron—Nausea—Gemcitabine—urinary bladder cancer	0.00033	0.00158	CcSEcCtD
Mirabegron—Vision blurred—Methotrexate—urinary bladder cancer	0.000329	0.00157	CcSEcCtD
Mirabegron—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000328	0.00157	CcSEcCtD
Mirabegron—Rash—Cisplatin—urinary bladder cancer	0.000327	0.00157	CcSEcCtD
Mirabegron—Dermatitis—Cisplatin—urinary bladder cancer	0.000327	0.00156	CcSEcCtD
Mirabegron—Diarrhoea—Etoposide—urinary bladder cancer	0.000325	0.00156	CcSEcCtD
Mirabegron—Nausea—Fluorouracil—urinary bladder cancer	0.000325	0.00156	CcSEcCtD
Mirabegron—Eye disorder—Doxorubicin—urinary bladder cancer	0.000324	0.00155	CcSEcCtD
Mirabegron—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000322	0.00154	CcSEcCtD
Mirabegron—Back pain—Epirubicin—urinary bladder cancer	0.000316	0.00151	CcSEcCtD
Mirabegron—Dizziness—Etoposide—urinary bladder cancer	0.000314	0.0015	CcSEcCtD
Mirabegron—Nausea—Cisplatin—urinary bladder cancer	0.000308	0.00148	CcSEcCtD
Mirabegron—Vision blurred—Epirubicin—urinary bladder cancer	0.000307	0.00147	CcSEcCtD
Mirabegron—Rash—Etoposide—urinary bladder cancer	0.000299	0.00143	CcSEcCtD
Mirabegron—Dermatitis—Etoposide—urinary bladder cancer	0.000299	0.00143	CcSEcCtD
Mirabegron—Headache—Etoposide—urinary bladder cancer	0.000298	0.00143	CcSEcCtD
Mirabegron—Arthralgia—Methotrexate—urinary bladder cancer	0.000297	0.00142	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000295	0.00141	CcSEcCtD
Mirabegron—Back pain—Doxorubicin—urinary bladder cancer	0.000292	0.0014	CcSEcCtD
Mirabegron—Palpitations—Epirubicin—urinary bladder cancer	0.000288	0.00138	CcSEcCtD
Mirabegron—Vision blurred—Doxorubicin—urinary bladder cancer	0.000284	0.00136	CcSEcCtD
Mirabegron—Infection—Methotrexate—urinary bladder cancer	0.000283	0.00135	CcSEcCtD
Mirabegron—Nausea—Etoposide—urinary bladder cancer	0.000282	0.00135	CcSEcCtD
Mirabegron—Hypertension—Epirubicin—urinary bladder cancer	0.000282	0.00135	CcSEcCtD
Mirabegron—Arthralgia—Epirubicin—urinary bladder cancer	0.000278	0.00133	CcSEcCtD
Mirabegron—Skin disorder—Methotrexate—urinary bladder cancer	0.000276	0.00132	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000276	0.00132	CcSEcCtD
Mirabegron—Dry mouth—Epirubicin—urinary bladder cancer	0.000272	0.0013	CcSEcCtD
Mirabegron—Palpitations—Doxorubicin—urinary bladder cancer	0.000267	0.00128	CcSEcCtD
Mirabegron—Infection—Epirubicin—urinary bladder cancer	0.000264	0.00127	CcSEcCtD
Mirabegron—Hypertension—Doxorubicin—urinary bladder cancer	0.000261	0.00125	CcSEcCtD
Mirabegron—Tachycardia—Epirubicin—urinary bladder cancer	0.00026	0.00124	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000259	0.00124	CcSEcCtD
Mirabegron—Skin disorder—Epirubicin—urinary bladder cancer	0.000259	0.00124	CcSEcCtD
Mirabegron—Arthralgia—Doxorubicin—urinary bladder cancer	0.000257	0.00123	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000255	0.00122	CcSEcCtD
Mirabegron—Dry mouth—Doxorubicin—urinary bladder cancer	0.000251	0.0012	CcSEcCtD
Mirabegron—Dyspepsia—Methotrexate—urinary bladder cancer	0.00025	0.0012	CcSEcCtD
Mirabegron—ABCB1—lymph node—urinary bladder cancer	0.000248	0.00704	CbGeAlD
Mirabegron—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000246	0.00118	CcSEcCtD
Mirabegron—Fatigue—Methotrexate—urinary bladder cancer	0.000245	0.00118	CcSEcCtD
Mirabegron—Infection—Doxorubicin—urinary bladder cancer	0.000245	0.00117	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000243	0.00116	CcSEcCtD
Mirabegron—Tachycardia—Doxorubicin—urinary bladder cancer	0.00024	0.00115	CcSEcCtD
Mirabegron—Skin disorder—Doxorubicin—urinary bladder cancer	0.000239	0.00115	CcSEcCtD
Mirabegron—Dyspepsia—Epirubicin—urinary bladder cancer	0.000234	0.00112	CcSEcCtD
Mirabegron—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000233	0.00111	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.00023	0.0011	CcSEcCtD
Mirabegron—Fatigue—Epirubicin—urinary bladder cancer	0.00023	0.0011	CcSEcCtD
Mirabegron—Constipation—Epirubicin—urinary bladder cancer	0.000228	0.00109	CcSEcCtD
Mirabegron—Urticaria—Methotrexate—urinary bladder cancer	0.000226	0.00108	CcSEcCtD
Mirabegron—Abdominal pain—Methotrexate—urinary bladder cancer	0.000225	0.00108	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000224	0.00108	CcSEcCtD
Mirabegron—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000218	0.00104	CcSEcCtD
Mirabegron—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000217	0.00104	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000213	0.00102	CcSEcCtD
Mirabegron—Fatigue—Doxorubicin—urinary bladder cancer	0.000212	0.00102	CcSEcCtD
Mirabegron—Urticaria—Epirubicin—urinary bladder cancer	0.000211	0.00101	CcSEcCtD
Mirabegron—Constipation—Doxorubicin—urinary bladder cancer	0.000211	0.00101	CcSEcCtD
Mirabegron—Abdominal pain—Epirubicin—urinary bladder cancer	0.00021	0.00101	CcSEcCtD
Mirabegron—Asthenia—Methotrexate—urinary bladder cancer	0.000204	0.000978	CcSEcCtD
Mirabegron—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000201	0.000965	CcSEcCtD
Mirabegron—Pruritus—Methotrexate—urinary bladder cancer	0.000201	0.000964	CcSEcCtD
Mirabegron—Urticaria—Doxorubicin—urinary bladder cancer	0.000196	0.000938	CcSEcCtD
Mirabegron—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000195	0.000933	CcSEcCtD
Mirabegron—Diarrhoea—Methotrexate—urinary bladder cancer	0.000195	0.000933	CcSEcCtD
Mirabegron—Asthenia—Epirubicin—urinary bladder cancer	0.000191	0.000915	CcSEcCtD
Mirabegron—Pruritus—Epirubicin—urinary bladder cancer	0.000188	0.000902	CcSEcCtD
Mirabegron—Dizziness—Methotrexate—urinary bladder cancer	0.000188	0.000901	CcSEcCtD
Mirabegron—Diarrhoea—Epirubicin—urinary bladder cancer	0.000182	0.000873	CcSEcCtD
Mirabegron—Rash—Methotrexate—urinary bladder cancer	0.000179	0.000859	CcSEcCtD
Mirabegron—Dermatitis—Methotrexate—urinary bladder cancer	0.000179	0.000859	CcSEcCtD
Mirabegron—Headache—Methotrexate—urinary bladder cancer	0.000178	0.000854	CcSEcCtD
Mirabegron—Asthenia—Doxorubicin—urinary bladder cancer	0.000177	0.000847	CcSEcCtD
Mirabegron—Dizziness—Epirubicin—urinary bladder cancer	0.000176	0.000843	CcSEcCtD
Mirabegron—Pruritus—Doxorubicin—urinary bladder cancer	0.000174	0.000835	CcSEcCtD
Mirabegron—Nausea—Methotrexate—urinary bladder cancer	0.000169	0.00081	CcSEcCtD
Mirabegron—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000169	0.000807	CcSEcCtD
Mirabegron—Rash—Epirubicin—urinary bladder cancer	0.000168	0.000804	CcSEcCtD
Mirabegron—Dermatitis—Epirubicin—urinary bladder cancer	0.000168	0.000803	CcSEcCtD
Mirabegron—Headache—Epirubicin—urinary bladder cancer	0.000167	0.000799	CcSEcCtD
Mirabegron—Dizziness—Doxorubicin—urinary bladder cancer	0.000163	0.00078	CcSEcCtD
Mirabegron—Nausea—Epirubicin—urinary bladder cancer	0.000158	0.000758	CcSEcCtD
Mirabegron—Rash—Doxorubicin—urinary bladder cancer	0.000155	0.000744	CcSEcCtD
Mirabegron—Dermatitis—Doxorubicin—urinary bladder cancer	0.000155	0.000743	CcSEcCtD
Mirabegron—Headache—Doxorubicin—urinary bladder cancer	0.000154	0.000739	CcSEcCtD
Mirabegron—Nausea—Doxorubicin—urinary bladder cancer	0.000146	0.000701	CcSEcCtD
Mirabegron—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.39e-05	0.00153	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.35e-05	0.00151	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—TYMP—urinary bladder cancer	3.34e-05	0.00151	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.21e-05	0.00145	CbGpPWpGaD
Mirabegron—ADRB3—GPCR ligand binding—CXCL8—urinary bladder cancer	3.13e-05	0.00141	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	3.08e-05	0.00139	CbGpPWpGaD
Mirabegron—ALB—Folate Metabolism—TP53—urinary bladder cancer	3.08e-05	0.00139	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—NAT2—urinary bladder cancer	3.02e-05	0.00136	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.97e-05	0.00134	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.94e-05	0.00133	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—TYMP—urinary bladder cancer	2.93e-05	0.00132	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTZ1—urinary bladder cancer	2.84e-05	0.00128	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.82e-05	0.00127	CbGpPWpGaD
Mirabegron—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	2.78e-05	0.00125	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.72e-05	0.00123	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.71e-05	0.00122	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.7e-05	0.00122	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTO2—urinary bladder cancer	2.7e-05	0.00122	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NAT1—urinary bladder cancer	2.7e-05	0.00122	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—RBX1—urinary bladder cancer	2.66e-05	0.0012	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—NAT2—urinary bladder cancer	2.65e-05	0.0012	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.65e-05	0.0012	CbGpPWpGaD
Mirabegron—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.65e-05	0.0012	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—RRM2—urinary bladder cancer	2.61e-05	0.00118	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	2.51e-05	0.00113	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TSC1—urinary bladder cancer	2.5e-05	0.00113	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.49e-05	0.00112	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	2.47e-05	0.00111	CbGpPWpGaD
Mirabegron—ALB—Metabolism—UGT2B7—urinary bladder cancer	2.47e-05	0.00111	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—HPGDS—urinary bladder cancer	2.42e-05	0.00109	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—ENO2—urinary bladder cancer	2.42e-05	0.00109	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.4e-05	0.00108	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—JAG1—urinary bladder cancer	2.38e-05	0.00107	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	2.37e-05	0.00107	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.37e-05	0.00107	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.36e-05	0.00107	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.36e-05	0.00107	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	2.35e-05	0.00106	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GSTT1—urinary bladder cancer	2.35e-05	0.00106	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.34e-05	0.00105	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.31e-05	0.00104	CbGpPWpGaD
Mirabegron—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	2.3e-05	0.00104	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.29e-05	0.00103	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—RRM2—urinary bladder cancer	2.29e-05	0.00103	CbGpPWpGaD
Mirabegron—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	2.27e-05	0.00102	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	2.23e-05	0.001	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NAT1—urinary bladder cancer	2.23e-05	0.001	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CYP4B1—urinary bladder cancer	2.22e-05	0.001	CbGpPWpGaD
Mirabegron—SLCO1A2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.2e-05	0.00099	CbGpPWpGaD
Mirabegron—BCHE—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	2.18e-05	0.000983	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	2.17e-05	0.00098	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	2.16e-05	0.000974	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ENO2—urinary bladder cancer	2.12e-05	0.000956	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—HPGDS—urinary bladder cancer	2.12e-05	0.000956	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IFNA2—urinary bladder cancer	2.12e-05	0.000954	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.11e-05	0.000951	CbGpPWpGaD
Mirabegron—ALB—Metabolism—SLC19A1—urinary bladder cancer	2.1e-05	0.000945	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GSTT1—urinary bladder cancer	2.06e-05	0.000928	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PRSS3—urinary bladder cancer	2.04e-05	0.000921	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	2.04e-05	0.000918	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.03e-05	0.000913	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—RHOA—urinary bladder cancer	2.01e-05	0.000907	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.01e-05	0.000905	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.98e-05	0.000894	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—NQO1—urinary bladder cancer	1.95e-05	0.000879	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.95e-05	0.000877	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.94e-05	0.000874	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—S100B—urinary bladder cancer	1.93e-05	0.000869	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.89e-05	0.000852	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.84e-05	0.000828	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.83e-05	0.000827	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—RHOA—urinary bladder cancer	1.83e-05	0.000824	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	1.82e-05	0.000823	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.79e-05	0.000807	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.77e-05	0.000796	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.75e-05	0.00079	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—NCOR1—urinary bladder cancer	1.73e-05	0.000781	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.73e-05	0.000781	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—IGF1—urinary bladder cancer	1.73e-05	0.000779	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—NQO1—urinary bladder cancer	1.71e-05	0.000771	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.69e-05	0.000764	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.69e-05	0.000762	CbGpPWpGaD
Mirabegron—ADRB3—GPCR downstream signaling—IL2—urinary bladder cancer	1.69e-05	0.000761	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.69e-05	0.000761	CbGpPWpGaD
Mirabegron—BCHE—Neuronal System—HRAS—urinary bladder cancer	1.67e-05	0.000753	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.66e-05	0.000748	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.65e-05	0.000743	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.64e-05	0.000739	CbGpPWpGaD
Mirabegron—ALB—Metabolism—TYMP—urinary bladder cancer	1.63e-05	0.000737	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GSTP1—urinary bladder cancer	1.63e-05	0.000733	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.61e-05	0.000727	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—CXCL8—urinary bladder cancer	1.6e-05	0.000723	CbGpPWpGaD
Mirabegron—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.59e-05	0.000718	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.57e-05	0.000709	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.57e-05	0.000707	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.57e-05	0.000707	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.54e-05	0.000692	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—IL2—urinary bladder cancer	1.53e-05	0.000691	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TERT—urinary bladder cancer	1.53e-05	0.000688	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—TYMS—urinary bladder cancer	1.51e-05	0.000681	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—PLAU—urinary bladder cancer	1.5e-05	0.000677	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—NCOR1—urinary bladder cancer	1.49e-05	0.000673	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GSTM1—urinary bladder cancer	1.49e-05	0.000673	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NAT2—urinary bladder cancer	1.48e-05	0.000666	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.46e-05	0.000656	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.46e-05	0.000656	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.45e-05	0.000652	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.43e-05	0.000645	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—GPX1—urinary bladder cancer	1.43e-05	0.000645	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GSTP1—urinary bladder cancer	1.43e-05	0.000643	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.4e-05	0.000633	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—ERCC2—urinary bladder cancer	1.4e-05	0.000633	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—FGFR3—urinary bladder cancer	1.4e-05	0.000632	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of proteins—CXCL8—urinary bladder cancer	1.39e-05	0.000627	CbGpPWpGaD
Mirabegron—BCHE—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.38e-05	0.000622	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.37e-05	0.000619	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—ESR1—urinary bladder cancer	1.36e-05	0.000614	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.35e-05	0.000608	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.33e-05	0.0006	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—TYMS—urinary bladder cancer	1.33e-05	0.000598	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—MTHFR—urinary bladder cancer	1.32e-05	0.000595	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GSTM1—urinary bladder cancer	1.31e-05	0.000591	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—NCOR1—urinary bladder cancer	1.31e-05	0.000591	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.31e-05	0.00059	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.3e-05	0.000585	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.29e-05	0.000584	CbGpPWpGaD
Mirabegron—ALB—Metabolism—RRM2—urinary bladder cancer	1.28e-05	0.000575	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—GPX1—urinary bladder cancer	1.26e-05	0.000566	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.24e-05	0.000559	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—ERCC2—urinary bladder cancer	1.23e-05	0.000555	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IGF1—urinary bladder cancer	1.22e-05	0.000552	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.22e-05	0.00055	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.2e-05	0.00054	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CREBBP—urinary bladder cancer	1.19e-05	0.000538	CbGpPWpGaD
Mirabegron—ALB—Metabolism—HPGDS—urinary bladder cancer	1.18e-05	0.000533	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ENO2—urinary bladder cancer	1.18e-05	0.000533	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IGF1—urinary bladder cancer	1.18e-05	0.000531	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.17e-05	0.000529	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—EGFR—urinary bladder cancer	1.17e-05	0.000528	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—MTHFR—urinary bladder cancer	1.16e-05	0.000522	CbGpPWpGaD
Mirabegron—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.15e-05	0.00052	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTT1—urinary bladder cancer	1.15e-05	0.000517	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.13e-05	0.00051	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.13e-05	0.000509	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—RHOA—urinary bladder cancer	1.12e-05	0.000505	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.12e-05	0.000504	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—KRAS—urinary bladder cancer	1.11e-05	0.000499	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.1e-05	0.000497	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—RHOA—urinary bladder cancer	1.08e-05	0.000487	CbGpPWpGaD
Mirabegron—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.07e-05	0.000484	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PPARG—urinary bladder cancer	1.07e-05	0.000483	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.05e-05	0.000475	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.04e-05	0.000467	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.04e-05	0.000467	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—CREBBP—urinary bladder cancer	1.03e-05	0.000464	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1e-05	0.000453	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—ERBB2—urinary bladder cancer	9.99e-06	0.00045	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	9.75e-06	0.00044	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ENO2—urinary bladder cancer	9.75e-06	0.00044	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NQO1—urinary bladder cancer	9.52e-06	0.000429	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CXCL8—urinary bladder cancer	9.47e-06	0.000427	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	9.46e-06	0.000426	CbGpPWpGaD
Mirabegron—ADRB3—Signaling by GPCR—HRAS—urinary bladder cancer	9.41e-06	0.000424	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—IL2—urinary bladder cancer	9.41e-06	0.000424	CbGpPWpGaD
Mirabegron—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.4e-06	0.000424	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PPARG—urinary bladder cancer	9.39e-06	0.000423	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.24e-06	0.000416	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—IL2—urinary bladder cancer	9.05e-06	0.000408	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—CREBBP—urinary bladder cancer	9.02e-06	0.000407	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CCND1—urinary bladder cancer	8.83e-06	0.000398	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TYMP—urinary bladder cancer	8.82e-06	0.000398	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MMP9—urinary bladder cancer	8.57e-06	0.000386	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—CDKN1A—urinary bladder cancer	8.54e-06	0.000385	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—PTEN—urinary bladder cancer	8.52e-06	0.000384	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—EP300—urinary bladder cancer	8.44e-06	0.00038	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTGS2—urinary bladder cancer	8.42e-06	0.00038	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NQO1—urinary bladder cancer	8.34e-06	0.000376	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—SRC—urinary bladder cancer	8.21e-06	0.00037	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EP300—urinary bladder cancer	8.13e-06	0.000366	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.06e-06	0.000363	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NAT2—urinary bladder cancer	7.98e-06	0.00036	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTP1—urinary bladder cancer	7.94e-06	0.000358	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—SRC—urinary bladder cancer	7.9e-06	0.000356	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NQO1—urinary bladder cancer	7.86e-06	0.000354	CbGpPWpGaD
Mirabegron—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.68e-06	0.000346	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTGS2—urinary bladder cancer	7.39e-06	0.000333	CbGpPWpGaD
Mirabegron—ALB—Metabolism—TYMS—urinary bladder cancer	7.38e-06	0.000333	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—PTEN—urinary bladder cancer	7.34e-06	0.000331	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GSTM1—urinary bladder cancer	7.3e-06	0.000329	CbGpPWpGaD
Mirabegron—ALB—Metabolism—NCOR1—urinary bladder cancer	7.3e-06	0.000329	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—MYC—urinary bladder cancer	7.08e-06	0.000319	CbGpPWpGaD
Mirabegron—SLCO1A2—Metabolism—EP300—urinary bladder cancer	7e-06	0.000316	CbGpPWpGaD
Mirabegron—ALB—Metabolism—GPX1—urinary bladder cancer	6.99e-06	0.000315	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTP1—urinary bladder cancer	6.96e-06	0.000314	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—EGFR—urinary bladder cancer	6.93e-06	0.000312	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.89e-06	0.00031	CbGpPWpGaD
Mirabegron—ALB—Metabolism—ERCC2—urinary bladder cancer	6.86e-06	0.000309	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—KRAS—urinary bladder cancer	6.8e-06	0.000306	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.56e-06	0.000296	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—KRAS—urinary bladder cancer	6.54e-06	0.000295	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—TYMS—urinary bladder cancer	6.47e-06	0.000292	CbGpPWpGaD
Mirabegron—ALB—Metabolism—MTHFR—urinary bladder cancer	6.45e-06	0.000291	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—PTEN—urinary bladder cancer	6.44e-06	0.00029	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—NCOR1—urinary bladder cancer	6.39e-06	0.000288	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GSTM1—urinary bladder cancer	6.39e-06	0.000288	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.38e-06	0.000287	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.38e-06	0.000287	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.19e-06	0.000279	CbGpPWpGaD
Mirabegron—BCHE—Metabolism—EP300—urinary bladder cancer	6.14e-06	0.000277	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—GPX1—urinary bladder cancer	6.12e-06	0.000276	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.1e-06	0.000275	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—TP53—urinary bladder cancer	6.04e-06	0.000272	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	6.03e-06	0.000272	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	6.03e-06	0.000272	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—ERCC2—urinary bladder cancer	6.01e-06	0.000271	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—TP53—urinary bladder cancer	5.81e-06	0.000262	CbGpPWpGaD
Mirabegron—ALB—Hemostasis—HRAS—urinary bladder cancer	5.78e-06	0.00026	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.77e-06	0.00026	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.67e-06	0.000255	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—MTHFR—urinary bladder cancer	5.65e-06	0.000255	CbGpPWpGaD
Mirabegron—ADRB3—Signaling Pathways—HRAS—urinary bladder cancer	5.56e-06	0.000251	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.33e-06	0.00024	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PPARG—urinary bladder cancer	5.23e-06	0.000236	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.14e-06	0.000232	CbGpPWpGaD
Mirabegron—ALB—Metabolism—CREBBP—urinary bladder cancer	5.02e-06	0.000227	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PPARG—urinary bladder cancer	4.58e-06	0.000207	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.4e-06	0.000198	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.32e-06	0.000195	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.29e-06	0.000193	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.15e-06	0.000187	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTGS2—urinary bladder cancer	4.11e-06	0.000185	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—TYMS—urinary bladder cancer	3.99e-06	0.00018	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	3.94e-06	0.000178	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	3.94e-06	0.000178	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.77e-06	0.00017	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.7e-06	0.000167	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.6e-06	0.000163	CbGpPWpGaD
Mirabegron—ALB—Metabolism—PTEN—urinary bladder cancer	3.59e-06	0.000162	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.48e-06	0.000157	CbGpPWpGaD
Mirabegron—ALB—Metabolism—EP300—urinary bladder cancer	3.42e-06	0.000154	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.4e-06	0.000153	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—PTEN—urinary bladder cancer	3.14e-06	0.000142	CbGpPWpGaD
Mirabegron—ABCB1—Metabolism—EP300—urinary bladder cancer	3e-06	0.000135	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.96e-06	0.000134	CbGpPWpGaD
Mirabegron—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.83e-06	0.000127	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.82e-06	0.000127	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.71e-06	0.000122	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.22e-06	0.0001	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.94e-06	8.73e-05	CbGpPWpGaD
Mirabegron—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.85e-06	8.33e-05	CbGpPWpGaD
